still buying arry , 89% institutional ownership and look at their pipeline, not to mention royalties only will pay arry
you better do your homework ARRY will eat ONTY and #$%$ it out. Compare the pipelines junior
A closely watched immune system-boosting drug cocktail from Britain's AstraZeneca shows promise in advanced lung cancer, despite adverse side effects in a number of patients.
Researchers said on Wednesday that the combination of the experimental drugs MEDI4736 and tremelimumab had "a manageable safety profile with evidence of clinical activity, including in PD-L1 negative disease".
A Single arm, non-randomized, open-label, phase I,evaluated Binimetinib in combination with G and C in pts with untreated ABC, who had advanced measurable disease, ECOG 0-1, adequate bone marrow, renal, hepatic and cardiac function. The primary endpoint was to determine the MTD. Tumor tissue for targeted gene sequencing, blood samples for peripheral blood pERK expression and cell cycle analysis were evaluated. Patients received oral Binimetinib twice daily with G and C IV infusions day 8 and 15 of a 21 days cycle in a standard 3 + 3 dose escalation scheme. Binimetinib was held for 2 days prior to and on day of each G and C infusion. Results: Between 09/13 and 08/14, 12 pts were enrolled. Male = 5, Female = 7. Median age 64 years (range 48- 76). Intrahepatic cholangiocarcinoma (IHC) = 8, gallbladder cancer = 3, 1 patient mixed IHC/Hepatocellular carcinoma. 1 pt received prior adjuvant G. Best response: 6 PR (50%), 4 SD (33%), 2 PD (17%). Median progression-free survival (PFS) was 6.4 months (95% CI 1.7 – 10.9), Median OS was 9.1 months (95% CI 1.7 – 16.1). 5 pts remain on study. See table 1 for dose limiting toxicities. Conclusions: The MTDs of Binimetinib, G and C were 45mg PO BID, 800 mg/m2 and C 20mg/m2 respectively. Encouraging activity of the combination was noted. An expansion single arm phase II trial evaluating the safety and activity of Binimetinib at this dose with C & G is underway in patients with untreated metastatic ABC (clinicaltrials.gov NCT01828034). Clinical trial information: NCT01828034